These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 23659299)

  • 1. Controlling serogroup B invasive meningococcal disease: the Canadian perspective.
    Bettinger JA; Deeks SL; Halperin SA; Tsang R; Scheifele DW
    Expert Rev Vaccines; 2013 May; 12(5):505-17. PubMed ID: 23659299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neisseria meningitidis B vaccines.
    Panatto D; Amicizia D; Lai PL; Gasparini R
    Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults.
    Toneatto D; Oster P; deBoer AC; Emerson A; Santos GF; Ypma E; DeTora L; Pizza M; Kimura A; Dull P
    Hum Vaccin; 2011 Jul; 7(7):781-91. PubMed ID: 21734467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances towards the prevention of meningococcal B disease: a multidimensional story.
    Roderick M; Finn A
    J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Meningococcal serogroup B vaccines].
    Dommergues MA
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S65-9. PubMed ID: 22883369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal serogroup B infections: a search for a broadly protective vaccine.
    Vermont CL; van den Dobbelsteen GP
    Expert Rev Vaccines; 2003 Oct; 2(5):673-81. PubMed ID: 14711328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Meningococcal vaccines: from polysaccharide to conjugate vaccines].
    Cohen R; Levy C
    Arch Pediatr; 2012 Sep; 19 Suppl 2():S61-4. PubMed ID: 22883368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.
    Whelan J; Bambini S; Biolchi A; Brunelli B; Robert-Du Ry van Beest Holle M
    Expert Rev Vaccines; 2015 May; 14(5):713-36. PubMed ID: 25603916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolving meningococcal immunization strategies.
    Sáfadi MA; Bettinger JA; Maturana GM; Enwere G; Borrow R;
    Expert Rev Vaccines; 2015 Apr; 14(4):505-17. PubMed ID: 25494168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The next chapter for group B meningococcal vaccines.
    Wang NY; Pollard AJ
    Crit Rev Microbiol; 2018 Feb; 44(1):95-111. PubMed ID: 28557577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand.
    Arnold R; Galloway Y; McNicholas A; O'Hallahan J
    Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New Zealand.
    Lennon D; Jackson C; Wong S; Horsfall M; Stewart J; Reid S
    Clin Infect Dis; 2009 Aug; 49(4):597-605. PubMed ID: 19622040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.
    Soriano-Gabarró M; Rosenstein N; LaForce FM
    J Health Popul Nutr; 2004 Sep; 22(3):275-85. PubMed ID: 15609780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Challenges and progress in the development of a serogroup B meningococcal vaccine.
    Lewis S; Sadarangani M; Hoe JC; Pollard AJ
    Expert Rev Vaccines; 2009 Jun; 8(6):729-45. PubMed ID: 19485754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization strategies for the control of serogroup C meningococcal disease in developed countries.
    De Wals P
    Expert Rev Vaccines; 2006 Apr; 5(2):269-75. PubMed ID: 16608426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges for development of meningococcal vaccines in infants and children.
    Deasy A; Read RC
    Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Impact of Meningococcal Serogroup A Conjugate Vaccine Introduction on Second-Year-of-Life Vaccination Coverage in Burkina Faso.
    Zoma RL; Walldorf JA; Tarbangdo F; Patel JC; Diallo AO; Nkwenkeu SF; Kambou L; Nikiema M; Ouedraogo A; Bationo AB; Ouili R; Badolo H; Sawadogo G; Krishnaswamy A; Hatcher C; Hyde TB; Aké F; Novak RT; Wannemuehler K; Mirza I; Medah I; Soeters HM
    J Infect Dis; 2019 Oct; 220(220 Suppl 4):S233-S243. PubMed ID: 31671442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.